Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Gains from Sales and Divestitures (2022 - 2026)

Treace Medical Concepts filings provide 4 years of Gains from Sales and Divestitures readings, the most recent being $7775.0 for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 97.73% to $7775.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $7775.0, a 97.73% decrease, with the full-year FY2025 number at $7775.0, down 97.73% from a year prior.
  • Gains from Sales and Divestitures hit $7775.0 in Q4 2025 for Treace Medical Concepts, down from $342012.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $342012.0 in Q4 2024 to a low of $6223.0 in Q4 2022.
  • Median Gains from Sales and Divestitures over the past 4 years was $78847.0 (2023), compared with a mean of $126482.2.
  • Biggest five-year swings in Gains from Sales and Divestitures: surged 2309.11% in 2023 and later crashed 97.73% in 2025.
  • Treace Medical Concepts' Gains from Sales and Divestitures stood at $6223.0 in 2022, then surged by 2309.11% to $149919.0 in 2023, then surged by 128.13% to $342012.0 in 2024, then crashed by 97.73% to $7775.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $7775.0 (Q4 2025), $342012.0 (Q4 2024), and $149919.0 (Q4 2023) per Business Quant data.